Perl A, Martinelli G, Cortes J, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase 3 ADMIRAL trial. 24th Congress of EHA, abstract A876.
Fase I-onderzoek naar IL-10-producerende anti-CD19 CAR T-cellen bij r/r B-cel ALL
dec 2025 | Leukemie